Premium
Effect of halofenate on serum uric acid
Author(s) -
Aronow Wilbert S.,
Harding Phillip R.,
Khursheed Mohammed,
Vangrow Jack S.,
Papageorge's Nicholas P.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973143371
Subject(s) - hyperuricemia , hypertriglyceridemia , placebo , uric acid , medicine , gout , endocrinology , gastroenterology , triglyceride , cholesterol , alternative medicine , pathology
The effect of halofenate on serum uric acid levels was evaluated in 48 people with hypertriglyceridemia in a 14 month double‐blind study. A 2 month control period began 1 month after starting dietary control. Twenty‐five patients were then given placebo, and 23 patients were given 2 halofenate tab lets of 500 mg each once daily for 48 weeks. The mean serum uric acid level during the 48 weeks of halofenate administration decreased 38%. The mean serum uric acid level during the 48 weeks of placebo administration decreased 3%. In comparison with placebo, halofenate caused a mean reduction in serum uric acid level of 35% (P < 0.01). Halofenate is especially of value in the treatment of patients with hyperuricemia and hypertriglyceridemia.